
Rentschler Biopharma to produce 100m doses of CureVac vaccine
Rentschler Biopharma SE is preparing large scale cGMP production and formulation of Curevac’s mRNA vaccine CVnCoV. Under a contract, signed in...

French biotech investors launch spin-out alliance
Argobio SAS has been kicked off with €50m of committed capital from Kurma Partners, and the state bank Bpifrance. Co-investors include Angelini...

Roche Phase III study misses COVID-19 endpoint
In the Phase III REMDACTA trial, the Swiss pharma major combined its cytokine storm blocker tocolizumab with Gilead Science’s viral transcription...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

Record year for Swiss biotech industry
Driven by the corona crisis, the Swiss biotech ecosystem is thriving as never before. This is evidenced by the Swiss Biotech Report from EY, the...

Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

Abingworth raises US-$465m for new life sciences fund
UK-US venture capitalist Abingworth yesterday announced the final closing of its 13th life sciences venture fund, ABV 8, at US$465m exceeding...